Status:
COMPLETED
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Lead Sponsor:
Cancer Research UK
Conditions:
brca1 Mutation Carrier
brca2 Mutation Carrier
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib an...
Detailed Description
OBJECTIVES: Primary * Assessment of Anti tumour activity to PARP-1 inhibitor rucaparib in patients with locally advanced or metastatic breast or advanced ovarian cancer shown to express the BRCA 1 o...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- All stages of the study (IV and oral):
- Patients must be proven known carriers of a mutation of BRCA1 or BRCA2 or considered to be highly likely to be carriers of a BRCA1 or 2 mutation\* (score of ≥ 20 as per Manchester criteria) and have histologically documented locally advanced or metastatic breast cancer or advanced ovarian cancer.
- \*Patients considered highly likely to be carriers will be tested after consenting and a BRCA1 or 2 mutation must be confirmed for the patient to be eligible to receive treatment.
- Oral stage 1 only:
- In addition to the above, patients with high grade serous ovarian cancer with unknown BRCA status may be entered into oral stage 1.
- Patients with ovarian cancer (including epithelial, fallopian tube cancer and primary peritoneal cancer) who have had no more than 5 prior chemotherapy regimens in the last 5 years. For the BRCA carriers \> 2 months must have elapsed since their last treatment with a carboplatin- or cisplatin-containing regimen or for high grade serous ovarian cancer patients ≥ 6 months.
- Patients with breast cancer who have had no more than 5 prior chemotherapy regimens in the last 5 years.
- Measurable disease as measured by X-ray, computerised tomography (CT), or MRI scan as defined by RECIST criteria. These measurements must be done within 4 weeks of the patient going on study. Clinical measurements must be done within one week of the patient going on study. Patients with bone disease must have other measurable disease for evaluation. Previously irradiated lesions cannot be used for measurable disease.
- Life expectancy of at least 12 weeks
- World Health Organisation (WHO) performance status of 0 or 1 (Appendix 1)
- Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week before the patient goes on study.
- Lab Test Value Required Haemoglobin (Hb) ≥9.0 g/dl Neutrophils ≥1.5 x 10\^9/L Platelets (Plts) ≥100 x 10\^9/L Serum bilirubin ≤1.5 x upper normal limit Alanine amino-transferase (ALT) and/or ≤ 2.5 x upper limit of normal (ULN) aspartate amino-transferase (AST) unless due to tumour in which case up to 5 x ULN is permissible Glomerular Filtration Rate (GFR) calculated either by the Wright formula ≥50 ml/min or Cockcroft-Gault formula or by isotope clearance measurement
- 18 years or over
- Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up
- EXCLUSION CRITERIA
- Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy, chemotherapy, biological agents or investigational agents during the previous 4 weeks (6 weeks for nitrosoureas and Mitomycin-C) before treatment.
- Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the Drug Development Office (DDO) should not exclude the patient.
- Known brain metastases.
- Female patients able to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrolment and agree to use two highly effective forms of contraception (oral, injected or implanted hormonal contraception and condom, have an intrauterine device and condom, diaphragm with spermicidal gel and condom, or are surgically sterilised) 4 weeks before entering the trial, during the trial and for 6 months afterwards are considered eligible.
- Male patients with partners of child-bearing potential (unless they agree to use one form of highly effective contraception such as a barrier method of condom plus spermicide during the trial and for 6 months afterwards).
- Major thoracic and/or abdominal surgery in the preceding 4 weeks from which the patient has not recovered.
- At high medical risk because of non-malignant systemic disease including active uncontrolled infection.
- Concurrent malignancies at other sites, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin and concurrent breast and ovarian carcinoma. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, are eligible for the study.
- Patients with active or unstable cardiac disease or history of myocardial infarction within 6 months. Patients with cardiovascular signs or symptoms should have a MUGA scan or echocardiogram, and those patients with left ventricular ejection fraction (LVEF) below the institutional limit of normal should be excluded.
- Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
- Patients who have already received a PARP inhibitor.
Exclusion
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT00664781
Start Date
December 1 2007
End Date
January 1 2015
Last Update
May 24 2016
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust
Birmingham, England, United Kingdom, B15 2TT
2
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, United Kingdom, LS9 7TF
3
Cancer Research UK and University College London Cancer Trials Centre
London, England, United Kingdom, W1T 4TJ
4
Christie Hospital
Manchester, England, United Kingdom, M20 4BX